Topoisomerase-I inhibitors in gynaecologic tumours

Annals of the Academy of Medicine Singapore

Volumn 27, Issue 5, 1998, Pages 683-687

  Verschraegen, Claire F ^a   Kudelka, A P ^b   Kavanagh, J J ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

Cervical cancer; Endometrial cancer; Ovarian neoplasms

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; DRUG EFFICACY; ENDOMETRIUM CANCER; GYNECOLOGIC CANCER; HUMAN; OVARY CANCER;

EID: 0032431892     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Wang J C. Recent studies of DNA topoisomerases. Biochim Biophys Acta 1987; 909:1.
2. Uemura T, Ohkura H, Adachi Y, et al. DNA topoisomerase II is required for condensation and separation of mitotic chromosomesin S. pombe. Cell 1986; 50:917-25.
3. Pommier Y. Review: DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Can Chemother Pharmacol 1993; 32:103-8.
4. Muller M T, Pfund W P, Mehta V B, Trask D K. Eukaryotic type I topisomerase is enriched in the nucleolus and catlytically active on ribosomal DNA. EMBO J 1985; 4:1237-43.
5. Fleischmann G, Pflugfelder G, Steiner E K, et al. Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome. Proc Natl Acad Sci USA 1984; 81:6958-62.
6. Garg L C, DiAngelo S, Jacob S T. Role of DNA topoisomerase I in the transcription of supercoiled rDNA gene. Proc Natl Acad Sci USA 1987; 84:3185-8.
7. Schneider E, Hsiang Y H, Liu L. DNA topoisomerase as anticancer drug targets. Adv Pharmacol 1990; 21:149-83.
8. D'Arpa P, Machlin P S, Ratrie H, Rothfield N F, Cleveland D W, Earnshaw W C. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc Natl Acad Sci USA 1988; 85:2543-7.
9. Juan C C, Hwang J, Liu A A, et al. Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. Proc Natl Acad Sci USA 1988; 85:8910-3.
10. Wang J C. DNA topoisomeraes: why so many? J Biol Chem 1991; 6:6659-62.
11. Champoux J. Evidence for an intermediate with a single-strand break in the reaction catalyzed by the DNA untwisting enzyme. Proc Natl Acad Sci USA 1976; 73:3488-91.
12. Lynn R M, Bjornsti M A, Caron P R, Wang J C. Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosin of Sacchaomyces cerevisiae DNA topoisomerase-I. Proc Natl Acad Sci USA 1989; 86:3559-63.
13. Liu L F, D'Arpa P. Topoisomerase-targeting antitumor drugs: mechanisms of cyotoxicity and resistance. Important Adv Oncol 1992:79-89.
14. Wall M E, Wani M C, Cooke E T, et al. Plant antitumor agents. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata. J Am Chem Soc 1996; 88:3888-90.
15. Giovanella B C, Hinz H R, Kozielski A J, et al. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20(S)-camptothecin. Cancer Res 1991; 51:3052-5.
16. Verschraegen C, Harris N, Steger M, Kavanagh J, Kudelka A, Giovanella B. Pharmacology study of multiple oral doses of 9-Nitrocamptothecin (9NC). Proc Am Assoc Can Res 1997; 38:A502.
17. Wang Y, et al. Preclinical evaluation of a new camptothecin derivative, CPT-11, on the subrenal capsule assay. Jpn J Cancer Chemother 1987; 14:1264.
18. Masumoto N, Nakano S, Esaki T, et al. Sequence dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. Anticancer Res 1995; 15:405-9.
19. Masumoto N, Nakano S, Esaki T, et al. Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous cell carcinoma cells. Int J Cancer 1995; 62:70-5.
20. Tamura K, Takada M, Masuda N, et al. Radiosensitization effect of CPT-11 against human lung tumor xenografts. Proc Am Assoc Cancer Res 1995; 36:A605.
21. Watanabe A, Nishiwaki K, Hasegawa Y, et al. Effects of taxotere (docetaxel) and irinotecan (CPT-11) combined with radiation on lung cancer cell lines. Proc Am Soc Clin Oncol 1995; 14:A494.
22. Mori H, Sawairi M, Itoh N, et al. Augmentation of antiproliferative activity of CPT-11, a new derivative of camptothecin, by tumor necrosis factor against proliferation of gynecologic tumor cell lines. Anticancer Drugs 1991; 2:469-74.
23. Valenti M, Morgavi P, Russo P, Pommier Y. Relationship between p53 expression, cell cycle and camptothecins-or TNF-sensitiviry [abstract]. Proc Annu Meet Am Assoc Cancer Res 1995; 36:A2660.
24. Chen S F, Rothenberg M L, Clark G, Degen D, Wajima M, Barton D, et al. Human tumor carboxylesterase activity correlates with CPT-11 cytotoxicity in vitro [abstract]. Proc Annu Meet Am Assoc Cancer Res 1995; 35:A2174.
25. Verschraegen C F, Levy T, Kudelka A P, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997; 15:625-31.
26. Look K Y, Blessing J A, Levenback C, Kohler M F, Chafe W E, Roman L D, et al. A Phase II trial of CPT-11 in chemotherapy-naive patients with recurrent squamous carcinoma of the cervix (SCC): A Gynecologic Oncology Group (GOG) Study. Soc Gynecol Oncol 1998; A134.
27. Chevallier B, Lhomme C, Dieras V, et al. Phase II trial of CPT-11 in advanced cervical carcinoma. EORTC Early Drug Development Meeting, June 21-24, 1995, Corfu Greece, 1995:92.
28. Takeuchi S, et al. An early phase II study of CPT-11 for gynecologic cancer. Jpn J Cancer Chemother 1991; 18:579.
29. Takeuchi S, et al. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Jpn J Cancer Chemother 1991; 18:1681.
30. Noda K, Sasaki H, Yamamoto K, Yamamoto T, Nishimura R, Sugiyama T, et al. Phase II trial of topotecan for cervical cancer of the uterus [abstract]. Proc Annu Meet Am Soc Clin Oncol 1996; 15:A754.
31. Sugiyama T, Takeushi S, Yakushiji M. Phase I study of irinotecan (CPT-11) in combination with cisplatin (CDDP) on cervical carcinoma. Proc Annu Meet Am Soc Clin Oncol 1994; 13:A856.
32. Sugiyama T, Noda K, Yakushiji M. Multicenter phase II trial of irinotecan (CPT-11) and cisplatin as first-line chemotherapy in recurrent or advanced cervical cancer: Japan CPT-11 study group trial. Proc Annu Meet Am Soc Clin Oncol 1998; 17:A1360.
33. Kudelka A P, Winn R, Edwards C L, et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 1997; 8:657-61.
34. Creemers G J, Bolis G, Scarfone G, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14:3056-61.
35. Armstrong D, Rowinsky E, Donehower R, et al. A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Annu Meet Am Soc Clin Oncol 1995; 14:A769.
36. Eisenhauer E, Hoskins P, Beare S, et al. Randomized phase II study of two schedules of topotecan epithelial ovarian cancer (EOC). Proc Annu Meet Soc Clin Oncol 1997; 16:1249.
37. Swisher E M, Mutch D G, Rader J S, et al. Topotecan ion platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997; 66:480-6.
38. Gordon A, ten Bokkel, Huinink W, Gore M, Malmstrom H, Krebs J B, et al. Pooled analysis of patients (pts) with recurrent ovarian cancer (ROC) who were treated with topotecan (T) after progression or failure on first-or second-line platinum (PLAT) and paclitaxel (P). Proc Annu Meet Am Soc Clin Oncol 1997; 16:A1319.
39. Rowinsky E K, Grochow L B, Hendricks C B, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10:647-56.
40. ten Bokel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15:2183-93.
41. Trimble E L, Adams J D, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11: 2405-10.
42. Plaxe S, Christen R, O'Quigley J, Braly P, Freddo J, McClay E, et al. Phase I trial of IP topotecan. Proc Annu Meet Am Soc Clin Oncol 1993; 12:A360.
43. Phase I clinical and pharmacokinetic study of a new topoisomerase inhibitor, GG211, given as a 72-hour continuous infusion. Br J Cancer 1994; 71(Suppl24):10.
44. Verschraegen C F, Natelson E A, Giovanella B C, Kavanagh J J, Kudelka A P, Freedman R S, et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 1998; 9:36-44.
45. Verschraegen C, Giovanella B, Armstrong K, Kavanagh J, Kudelka A, Steger M, et al. Phase II study of oral administration of 9-nitrocamptothecin in refractory ovarian cancer. Proc Am Soc Clin Oncol, 1997:A1356.
46. Mitsui I, Kumazawa E, Hirota Y, Aonuma M, Sugimori M, Ohsuki S, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 1995; 86:776-82.
47. Cao Z, Harris N, Mendoza J, Early J, Kozielski A, Varderman D, et al. Alkyl esters 9-nitrocamptothecin: Synthesis, toxicity and anti-tumor activity. Proc Am Assoc Cancer Res 1998; 39:A2859.